U.S. Trade Distributors Stock News

Johnson & Johnson (NYSE:JNJ) announced its 64th consecutive annual dividend increase, with a 3.1% raise. The company highlighted new product updates, including fresh real world and clinical trial data for its TECNIS PureSee intraocular lens. Johnson & Johnson also reported progress in MedTech with the launch of the VARIPULSE Pro pulsed field ablation system in Europe. For income focused investors, Johnson & Johnson's 64 year dividend growth streak reinforces its profile as a consistent...

Earlier this month, LiveRamp announced a partnership with Akkio to embed AI tooling into its data collaboration network and an expanded collaboration with Unity that brings RampID-based identity targeting to Unity’s mobile ad exchange covering 2.9 billion monthly active devices globally. Together, these moves deepen LiveRamp’s role at the center of AI-powered marketing workflows while broadening its reach across mobile gaming inventory for agencies and brands. Now we’ll explore how embedding...

Victoria's Secret (NYSE:VSCO) Chair Donna James has made her largest-ever personal share purchase in the company. Non executive director Anne Sheehan has bought Victoria's Secret shares for the first time. Both insider purchases were made at recent peak prices around the current share price of $49.94. Victoria's Secret, trading at $49.94, has had a 206.8% return over 1 year and a 50.7% return over 3 years, while year to date the stock shows a 6.4% decline. Recent shorter term moves are also...

Lockheed Martin (NYSE:LMT) secured a new $4.76b contract to increase PAC-3 MSE missile production for the U.S. Army through 2030. The agreement supports both U.S. and allied air and missile defense requirements over multiple years. The company also completed NASA's Artemis II mission with the Orion spacecraft, validating crewed deep space capabilities. For investors watching NYSE:LMT, this combination of a multiyear, multibillion-dollar defense contract and a successful Artemis II mission...

Saia (SAIA) has been drawing attention after recent share price moves, with the stock last closing at US$396.74. Investors are weighing this performance against its recent returns and current business fundamentals. See our latest analysis for Saia. That recent 23.6% 1 month share price return and 17.7% year to date share price return point to building momentum, while the 1 year total shareholder return of 16.5% reflects a more measured longer term outcome. If Saia's move has you thinking...

MercadoLibre (NasdaqGS:MELI) plans a major investment in Brazil for 2026 to expand its logistics and e-commerce operations. The plan includes 14 new fulfillment centers across the country. The company expects to hire about 10,000 employees as part of this expansion. The 2026 spending plan is about 50% higher than MercadoLibre's prior year outlay in Brazil. For you as an investor, this move highlights how central Brazil is to MercadoLibre's e-commerce and fintech ecosystem in Latin America...

Why Globe Life is on investors’ radar now Globe Life (GL) has drawn attention after recent share price moves, with the stock last closing at $147.55. Investors are weighing this level against the insurer’s current financial profile and return history. See our latest analysis for Globe Life. The recent 1-month share price return of 6.57% and 6.60% year to date sits alongside a 1-year total shareholder return of 22.75%, which points to momentum building rather than fading for Globe Life. If you...

If you are wondering whether Applied Materials at US$395.73 is still reasonably priced after a strong run, you are not alone. The stock has recorded returns of 11.7% over the last 7 days, 15.9% over 30 days, 47.2% year to date and 174.5% over the past year, which naturally raises questions about risk, reward and where value stands today. Recent coverage has focused on Applied Materials as a key player in semiconductor equipment, with investors closely watching how industry demand and capital...

CVS Health and the Federal Trade Commission have reached a proposed settlement related to insulin pricing practices involving CVS subsidiaries Caremark and Zinc Health Services. The consent agreement is designed to resolve complaints tied to the company’s pharmacy benefit manager activities in the insulin market. The settlement, once finalized, would address a key regulatory issue that has been affecting CVS Health’s PBM operations. For investors tracking NYSE:CVS, this regulatory...

In April 2026, Tapcheck announced a fully embedded integration with Paychex HR PEO, enabling eligible employees to access a portion of their earned wages instantly via the Tapcheck app or a Tapcheck Mastercard, without requiring payroll teams to adopt new systems or processes. This move highlights how Paychex is using real-time payroll and machine-learning-based balance calculations to broaden financial wellness tools for clients in complex staffing industries such as hospitality and senior...

If you are wondering whether Pinterest is starting to look attractively priced or still has more downside risk, its recent share performance gives you a lot to think about. The stock closed at US$18.02, with returns of a 1.3% decline over 7 days, a 0.9% decline over 30 days, a 32.2% decline year to date and a 30.3% decline over the past year, which may have shifted how the market views its potential. These moves have played out alongside ongoing user interest in visual search and shopping...

In April 2026, DXC Technology expanded its long-standing collaboration with ServiceNow and introduced new AI-powered Assure Smart Apps for insurers, aiming to modernize operations with modular, workflow-driven tools that can be deployed without overhauling core systems. By acting as ServiceNow’s “Customer Zero” for its Core Business Suite while simultaneously packaging those AI capabilities into pre-integrated insurance solutions, DXC is positioning itself as both an early enterprise adopter...

Goldman Sachs Group (NYSE:GS) reported first quarter profit that was 19% higher year over year. Global Banking & Markets delivered record revenues in the period. Management pointed to growth in investment banking fees, AI initiatives, and private credit as key contributors. ...........................................................The bank completed its acquisition of Innovator Capital Management, expanding its ETF platform and active fund offering. For investors tracking large global...

Context for Coterra Energy’s recent share performance Coterra Energy (CTRA) has drawn attention after recent share moves, including a 1 day return of around a 1.2% decline and a 4.8% decline over the past week, alongside stronger gains over the past month and the past 3 months. See our latest analysis for Coterra Energy. Zooming out, the recent share price pullback sits against a stronger backdrop, with a 24.1% year to date share price return and a 35.37% 1 year total shareholder return that...

Recent insider activity at Q2 Holdings (QTWO) has attracted attention, with nearly US$23 million of shares sold over the past three months and no insider buying. This has prompted questions about alignment between management and shareholders. See our latest analysis for Q2 Holdings. At a share price of US$47.98, Q2 Holdings has seen a 4.60% 1 day share price gain but a 90 day share price return decline of 30.27%, alongside a 36.40% 1 year total shareholder return decline and a very large 3...

Recently, SLB announced that its OneSubsea joint venture won a high-pressure, high-temperature multiphase boosting contract for Beacon Offshore’s Shenandoah deepwater field in the Gulf of America, alongside a long-term collaboration framework with PETRONAS Suriname and Subsea7 for integrated subsea developments in Suriname. These agreements underline how SLB’s advanced subsea and digital capabilities are being written into multi-year offshore development plans, potentially reinforcing the...

FDA grants Priority Review to ifinatamab deruxtecan, a B7-H3 antibody drug conjugate co-developed by Merck (NYSE:MRK) and Daiichi Sankyo. The filing covers adults with extensive-stage small cell lung cancer whose disease has relapsed after chemotherapy. If approved, this would be the first B7-H3 targeted medicine available for any cancer. For investors watching NYSE:MRK, this Priority Review highlights fresh momentum in Merck’s oncology pipeline alongside its existing cancer portfolio. The...

Rumors emerged that Nvidia is exploring an acquisition of a major PC manufacturer, with speculation centering on Dell Technologies (NYSE:DELL). The report suggested a potential deal that could link Nvidia's chips with a large PC and server footprint. Nvidia later denied pursuing any such acquisition, but the initial headlines coincided with a sharp move higher in Dell's share price. Dell Technologies sits at the intersection of PCs, servers, storage and enterprise solutions, which places it...

Wondering whether Gilead Sciences at around US$139 a share still offers value or if most of the opportunity is already reflected in the price, this article breaks that question down in plain terms. The stock shows a mixed recent picture, with a 0.2% return over the last 7 days, a 4.1% decline over 30 days, a 14.3% return year to date and a 35.1% return over 1 year that some investors may read as a strong payoff for sticking with the name. Recent coverage has focused on how Gilead Sciences...

In March 2026, West Pharmaceutical Services opened a new 165,000 square foot building at its Damastown, Dublin site, expanding contract services to include advanced automation and commercial-scale drug-handling capabilities for high-volume treatments such as diabetes and obesity therapies. This expansion deepens the West Vantage single-source offering across development, manufacturing, packaging, and regulatory support, aiming to streamline customers' paths from concept to commercial supply...

If you have been wondering whether Revvity is starting to look interesting on price, this breakdown will help you make sense of where the value case currently stands. Revvity shares last closed at US$92.64, after returns of 4.9% over the past week and 8.3% over the past month, while the year to date return is a 5.6% decline and the 1 year return is a 4.8% decline. These recent moves sit against a longer record that includes a 31.3% decline over 3 years and a 30.4% decline over 5 years, which...

Oklo (NYSE:OKLO) expects its first reactor to reach operational criticality by July 4. Criticality would mean achieving a self-sustaining nuclear reaction in the company’s initial microreactor. This milestone is important for moving Oklo’s advanced microreactor technology toward commercial use. Oklo focuses on advanced microreactors designed to provide compact nuclear power solutions. For investors watching the nuclear and clean energy space, this expected criticality event marks a shift in...

MediWound Ltd. recently announced that Vericel, its exclusive North American distributor for NexoBrid, secured a ten-year BARDA contract worth up to US$197 million to fund NexoBrid procurement, vendor-managed inventory, potential U.S. manufacturing, and development of new indications and formulations. The contract’s mix of immediate stockpile purchases, inventory services, and longer-term development funding highlights how government preparedness priorities can underpin Vericel’s burn-care...

If you are wondering whether Dollar Tree is attractively priced after a volatile few years, this article walks through how its current share price stacks up against several valuation checks. The stock closed at US$102.13, with returns of an 8.1% decline over 7 days, a 5.0% decline over 30 days, a 20.0% decline year to date, but 38.6% over 1 year, highlighting how quickly sentiment around value and risk can shift. Recent coverage has focused on Dollar Tree's repositioning within value retail...